NSPR vs ELMD vs ATEC vs ANGO vs PTGX

For growth investors, InspireMD, Inc.

(NSPR) is the stronger pick with 28. 1% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Electromed, Inc. (ELMD) offers the better valuation at 31. 2x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Electromed, Inc.

is actually cheaper at 24. 4x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -77. 0% for InspireMD, Inc. (NSPR). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus NSPR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 428% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), InspireMD, Inc.

(NSPR) is pulling ahead at 28. 1% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ATEC leads at 29. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Electromed, Inc.

(ELMD) is the more profitable company, earning 11. 8% net margin versus -543. 3% for InspireMD, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -547. 0% for NSPR. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Electromed, Inc.

(ELMD) trades at 24. 4x forward P/E versus 30. 6x for Protagonist Therapeutics, Inc. — 6. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Both have compounded well over 10 years (PTGX: +744. 9%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NSPR is a small-cap high-growth stock; ELMD is a small-cap high-growth stock; ATEC is a small-cap high-growth stock; ANGO is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.